High expression of SEZ6L2 as an independent prognostic Indicator in thyroid carcinoma

5Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Background: Seizure-related 6 homolog (mouse)-like 2 (SEZ6L2) is a type 1 transmembrane protein that is primarily expressed in the brain. In recent reports, SEZ6L2 has been found to be overexpressed in some cancers and can drive the progression of tumors. However, its function and mechanism in thyroid cancer remain unclear. Methods: In this article,we searched for the SEZ6L2 expressions in Pan-cancer on TCGA (The Cancer Genome Atlas) and evaluated these data using the TIMER2 method. Then, the immunohistochemical score (IHC score) of SEZ6L2 in cancer tissue was collected in human protein mapping (HPA) data. And we used CIBERSORT to assess the association between the levels of SEZ6L2 expression and the number of various immune cells in papillary thyroid carcinoma (PTC) tissue. Finally, Gene Expression Omnibus (GEO) analyses, real-time quantitative polymerase chain reaction (qRT-PCR) of tissues, and immunohistochemical staining were used to detect the result. Results: The article illustrated that a large number of cancers had a higher expression of SEZ6L2 compared to the control tissues. And the immunohistochemical score (IHC score) of SEZ6L2 in cancer tissue was considerably elevated compared to that in normal tissues SEZ6L2 was elevated in thyroid carcinoma (THCA) tissue, besides, GEO analyses, qRT-PCR of tissues, and immunohistochemical staining were conducted to test the results. Finally, the Kaplan-Meier survival analysis illustrated that the increased expression of SEZ6L2 was correlated with a dismal prognosis-higher SEZ6L2 is associated with shorter survival. And the univariate analysis illustrated that T stage, SEZ6L2 and Pathologic stage were related to the overall survival (OS), multivariate analysis stated that elevated expression of SEZ6L2 was an independent risk factor that affected progression-free interval (PFI) (P<0.05). Consequently, we found that the expression of SEZ6L2 was correlated with tumor-infiltrating immune cells by TIMER. Conclusions: SEZ6L2 was upregulated in patients with THCA and that increased expression of SEZ6L2 was related with clinical progression and was regarded as an independent risk factor for PFI. In THCA patients, the expression of SEZ6L2 could be a significant prognostic factor, which is expected to be a prospective biomarker for THCA in the future.

References Powered by Scopus

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

75829Citations
N/AReaders
Get full text

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

2307Citations
N/AReaders
Get full text

Association between microdeletion and microduplication at 16p11.2 and autism

1360Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Anti-SEZ6L2 antibodies in paraneoplastic cerebellar syndrome: case report and review of the literature

10Citations
N/AReaders
Get full text

Autoimmune cerebellar ataxia

2Citations
N/AReaders
Get full text

Overexpression of SEZ6L2 and Immune Infiltration in Cancer Based on Gene Image Diagnosis

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Luo, X., Chen, X., Chen, S., Gao, Q., Yang, H., & Zhao, D. (2022). High expression of SEZ6L2 as an independent prognostic Indicator in thyroid carcinoma. Gland Surgery, 11(2), 412–425. https://doi.org/10.21037/gs-22-37

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

60%

Researcher 2

40%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

33%

Engineering 2

33%

Biochemistry, Genetics and Molecular Bi... 1

17%

Neuroscience 1

17%

Save time finding and organizing research with Mendeley

Sign up for free